Today, a growing number of people, including children and young adults, are being subjected to various kinds of cancers, adding urgency to the search for treatments that are effective and tolerable. Families facing aggressive cancers often find themselves navigating therapies that can be physically demanding, particularly when standard treatments are rendered futile. Against that backdrop, Aminex Therapeutics has spent more than a decade pursuing a scientific pathway that remains elusive in the broader medicine world.
According to Jeff Judson, the company's Vice President, Aminex is currently conducting a clinical trial specifically targeting polyamine metabolism in cancer. Polyamines are naturally occurring compounds that tumor cells rely on to multiply rapidly and evade the immune system. The company's investigational approach combines its proprietary drug, AMXT 1501, with difluoromethylornithine (DFMO), a drug that recently gained FDA approval under the name Iwilfin for reducing relapse risk in children with neuroblastoma.
"Cancer cells require an abundance of polyamines to grow and multiply," Judson explains. "With our two-drug approach, the DFMO is designed to stop the cancer cell from producing its own polyamines, and the AMXT 1501 is designed to prevent the cancer from taking up polyamines from the bloodstream."
The strategy, Judson notes, attacks the problem from two directions at once. According to him, reducing access to both sources of polyamines may weaken cancer cells and reduce the immune suppression associated with tumor growth.
The origins of the company trace back to the work of Dr. Mark Burns, a PhD biochemist who serves as President and Chief Scientific Officer. Judson recounts that Burns discovered the underlying technology while working at another company. When that organization ceased operations, Burns acquired the patents and founded Aminex in 2009, dedicating the years that followed to advancing the science toward clinical development.
"Everybody wanted answers rooted in real scientific data. So we decided to keep a low profile, do our work, get some human data, and then tell the world," Judson says.
The company's scientific and financial trajectory has followed that very principle. Aminex has adopted a milestone-based funding strategy instead of pursuing large venture capital rounds. Judson credits former Chairman and CEO Jim Skaggs with helping craft an operating model that lies in raising solely the capital required to reach the next development milestone. "We have zero debt and no venture capital financing. Most of our investors simply want to participate in something they believe can make a difference," Judson says.
Clinical evidence forms a foundational pillar of the company's story. Judson points to an earlier study involving 56 patients whose cancers had progressed despite numerous prior therapies.
The research showed roughly half of the participants experienced clinical benefit from the two-drug combination, despite having undergone an average of ten different treatment attempts. The company has since advanced into a Phase 1b/2 trial evaluating AMXT 1501 and DFMO in patients with metastatic melanoma and ER-positive, HER-2 negative breast cancer, combined with current standards of care.
Equally significant, Judson says, is the treatment's delivery method and tolerability profile. "Patients take a few pills in the morning and later in the evening and continue living their lives," he says. "We've seen very mild side effects compared to what many cancer patients experience."
Current efforts extend beyond adult cancers. Aminex is collaborating with researchers involved in the Beat Childhood Cancer Consortium at the Penn State College of Medicine, conducting a pediatric trial examining the company's drug combination across several childhood cancers, including multiple brain tumors and neuroblastoma.
According to Judson, Aminex is donating the drugs while external investigators lead and fund the study. Independent pediatric research efforts are also underway at institutions in Australia, where researchers continue evaluating the role of polyamine-targeted therapies in treatment-resistant childhood cancers.
Recent regulatory developments have added momentum as the FDA has granted Orphan Drug Designation to AMXT 1501 in combination with DFMO for both neuroblastoma and malignant glioma, including diffuse intrinsic pontine glioma (DIPG), a highly aggressive pediatric brain cancer. Judson views these designations as encouraging signals as the company advances its clinical programs.
In the upcoming years, Aminex hopes to complete Phase 2 studies and ultimately partner with a larger pharmaceutical company capable of bringing the therapy to a broader patient population. Judson emphasizes that the company sees its approach as potentially complementary to existing cancer therapies rather than a standalone treatment.
Still, the company's sense of purpose remains rooted in the patients who currently have the fewest options. "Any improved treatment for cancer would be meaningful, but when you look at infants and young children facing cancers where effective treatments simply don't exist, that's what drives us every day," he says.
After years spent building evidence, Aminex Therapeutics now appears ready to bring its work into a wider view, guided by a belief that a small company focused on a single scientific question can still make a meaningful contribution to one of medicine's most difficult challenges.
